Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Update

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) saw a significant decrease in short interest during the month of July. As of July 15th, there was short interest totaling 26,452 shares, a decrease of 98.2% from the June 30th total of 1,511,367 shares. Based on an average daily volume of 67,658 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.2% of the shares of the company are short sold.

Enlivex Therapeutics Stock Down 3.7%

Shares of ENLV stock traded down $0.16 during mid-day trading on Friday, hitting $4.20. 106,559 shares of the stock were exchanged, compared to its average volume of 69,542. Enlivex Therapeutics has a 52-week low of $4.08 and a 52-week high of $31.50. The company has a market cap of $70.69 million, a PE ratio of -0.51 and a beta of 1.52. The firm has a fifty day moving average of $8.85 and a 200 day moving average of $12.74.

Hedge Funds Weigh In On Enlivex Therapeutics

Hedge funds have recently bought and sold shares of the business. Virtu Financial LLC purchased a new stake in shares of Enlivex Therapeutics in the fourth quarter valued at approximately $33,000. Invesco Ltd. purchased a new position in shares of Enlivex Therapeutics during the 4th quarter valued at approximately $43,000. XTX Topco Ltd grew its stake in Enlivex Therapeutics by 44.8% in the 4th quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock valued at $43,000 after acquiring an additional 19,132 shares during the period. Jane Street Group LLC grew its stake in Enlivex Therapeutics by 244.1% in the 4th quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock valued at $52,000 after acquiring an additional 52,553 shares during the period. Finally, Susquehanna International Group LLP purchased a new stake in Enlivex Therapeutics in the 3rd quarter worth $57,000. Hedge funds and other institutional investors own 1.02% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Zacks Research upgraded Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday. HC Wainwright lifted their price target on Enlivex Therapeutics from $195.00 to $300.00 and gave the company a “buy” rating in a research report on Tuesday, April 7th. Wall Street Zen upgraded Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Friday, June 26th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $247.50.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.